BioSpace News Archive

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, reported fourth quarter and full year 2021 financial results and provided business updates.

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that it will report financial results for its first quarter of fiscal 2022 ended February 28, 2022 on Wednesday, April 13, 2022.

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported financial results for the year ended December 31, 2021 and an update on recent activities.

Timber Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, provided a business update and announced financial results for the fourth quarter and year ended December 31, 2021.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in March 2022.

Aziyo Biologics, Inc. announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

Prestige Biopharma Limited a Singapore-based leading biopharmaceutical with operations in USA and South Korea, announced that the company has been recognized as the grand winner of the Bioprocessing Excellence in SEA.

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today reported its financial results for the full year 2021 and provided a business update.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced results of a retrospective, observational study describing the substantial burden of myelosuppression and its impact on healthcare resource utilization in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer.

CTI BioPharma Corp. reported its financial results for the fourth quarter and full year ended December 31, 2021.